348 related articles for article (PubMed ID: 34313538)
1. A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.
Gacesa R; Vich Vila A; Collij V; Mujagic Z; Kurilshikov A; Voskuil MD; Festen EAM; Wijmenga C; Jonkers DMAE; Dijkstra G; Fu J; Zhernakova A; Imhann F; Weersma RK
Gut Microbes; 2021; 13(1):1943288. PubMed ID: 34313538
[TBL] [Abstract][Full Text] [Related]
2. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study.
David LE; Surdea-Blaga T; Dumitrascu DL
Sao Paulo Med J; 2015; 133(4):343-9. PubMed ID: 26039537
[TBL] [Abstract][Full Text] [Related]
3. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
Menees SB; Powell C; Kurlander J; Goel A; Chey WD
Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.
Holtman GA; Lisman-van Leeuwen Y; Kollen BJ; Norbruis OF; Escher JC; Kindermann A; de Rijke YB; van Rheenen PF; Berger MY
Ann Fam Med; 2016 Sep; 14(5):437-45. PubMed ID: 27621160
[TBL] [Abstract][Full Text] [Related]
7. No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease.
Shutkever O; Gracie DJ; Young C; Wood HM; Taylor M; John Hamlin P; Ford AC; Quirke P
Inflamm Bowel Dis; 2018 Jun; 24(7):1597-1605. PubMed ID: 29668957
[TBL] [Abstract][Full Text] [Related]
8. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
9. Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study.
Bosch S; van Gaal N; Zuurbier RP; Covington JA; Wicaksono AN; Biezeveld MH; Benninga MA; Mulder CJ; de Boer NKH; de Meij TGJ
Inflamm Bowel Dis; 2018 Oct; 24(11):2468-2475. PubMed ID: 29788410
[TBL] [Abstract][Full Text] [Related]
10. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
[TBL] [Abstract][Full Text] [Related]
11. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
12. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
Campbell JP; Zierold C; Rode AM; Blocki FA; Vaughn BP
J Clin Gastroenterol; 2021 Mar; 55(3):239-243. PubMed ID: 32324678
[TBL] [Abstract][Full Text] [Related]
13. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
14. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
Schoepfer AM; Trummler M; Seeholzer P; Seibold-Schmid B; Seibold F
Inflamm Bowel Dis; 2008 Jan; 14(1):32-9. PubMed ID: 17924558
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease.
Kittanakom S; Shajib MS; Garvie K; Turner J; Brooks D; Odeh S; Issenman R; Chetty VT; Macri J; Khan WI
Can J Gastroenterol Hepatol; 2017; 2017():1450970. PubMed ID: 28491862
[No Abstract] [Full Text] [Related]
16. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
18. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome].
Li XG; Lu YM; Gu F; Yang XL
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):310-3. PubMed ID: 16778979
[TBL] [Abstract][Full Text] [Related]
19. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
20. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go?
Nemakayala DR; Cash BD
Curr Opin Gastroenterol; 2019 Jan; 35(1):58-62. PubMed ID: 30407259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
